Verification of efficacy and safety of ibandronate or denosumab for postmenopausal osteoporosis after 12-month treatment with romosozumab as sequential therapy: The prospective VICTOR study-Reference-Cited by-同舟云学术

Verification of efficacy and safety of ibandronate or denosumab for postmenopausal osteoporosis after 12-month treatment with romosozumab as sequential therapy: The prospective VICTOR study

Published:2022-09 Issue: Volume:162 Page:116480
ISSN:8756-3282
Container-title:Bone
language:en
Short-container-title:Bone

Author:

Kobayakawa Tomonori,Miyazaki Akiko,Takahashi Jun,Nakamura Yukio

Publisher

Elsevier BV

Subject

Histology,Physiology,Endocrinology, Diabetes and Metabolism

Reference30 articles.

1. European guidance for the diagnosis and management of osteoporosis in postmenopausal women;Kanis;Osteoporos Int.,2019

2. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial;Leder;Lancet,2015

3. Differential temporal effects of sclerostin antibody and parathyroid hormone on cancellous and cortical bone and quantitative differences in effects on the osteoblast lineage in young intact rats;Ominsky;Bone,2015

4. Time-dependent cellular and transcriptional changes in the osteoblast lineage associated with sclerostin antibody treatment in ovariectomized rats;Taylor;Bone,2016

5. Romosozumab Treatment in Postmenopausal Women with Osteoporosis;Cosman;The New England journal of medicine,2016

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Effectiveness and Safety of Romosozumab and Teriparatide in Postmenopausal Women With Osteoporosis;The Journal of Clinical Endocrinology & Metabolism;2024-07-16

2. Efficacy and safety of romosozumab: a meta-analysis of placebo-controlled trials;Journal of Bone and Mineral Metabolism;2024-07-08

3. Osteoporosis management-current and future perspectives – A systemic review;Journal of Orthopaedics;2024-07

4. Repurposing anti-osteoporosis drugs for autoimmune diseases: A two-sample Mendelian randomization study;Heliyon;2024-07

5. Denosumab vs. bisphosphonates in primary osteoporosis: a meta-analysis of comparative safety in randomized controlled trials;Osteoporosis International;2024-05-11